Advertisement
Azar proposes competition to combat high drug prices

Azar proposes competition to combat high drug prices

By Susannah Luthi  |  November 29, 2017

In his initial confirmation testimony, former pharma executive and HHS secretary nominee Alex Azar said he would stop drug manufacturers from gaming the system and blocking generic competitors from the market.

FDA to pave clearer path for generic drugs

FDA to pave clearer path for generic drugs

By Alex Kacik  |  November 29, 2017

The FDA's new guidance aims to make it easier for generic firms to plan how they can copy complex drugs like epinephrine auto-injectors, which should ultimately lower pharmaceutical prices.

States seek to expand lawsuit against generic-drug makers

States seek to expand lawsuit against generic-drug makers

By Associated Press  |  November 01, 2017

Connecticut and 45 other states are seeking to expand a federal antitrust lawsuit against generic-drug makers to include more manufacturers and medications, as well as senior executives at two companies.

Increasing transparency on generic drug cost data could save $4 billion

Increasing transparency on generic drug cost data could save $4 billion

By Alex Kacik  |  June 15, 2017

Making actual generic drug acquisition costs available to third-party payers would empower health plans to negotiate lower rates and essentially level the playing field in a pharmaceutical supply chain that's shrouded in secrecy, according to a new paper.

Hillary Clinton proposes federal panel to oversee drug prices

By Harris Meyer  |  September 03, 2016

Clinton proposes new enforcement mechanisms, including having the government buy and provide alternative therapies to patients, allowing temporary importation of lower-priced drugs from foreign countries and fining drug companies that excessively raise prices.

Blog: Mylan's sudden plans for a generic EpiPen

Blog: Mylan's sudden plans for a generic EpiPen

By Adam Rubenfire  |  August 31, 2016

Mylan made a somewhat surprising announcement Monday that it would launch a generic version of its EpiPen in several weeks and sell it for half the list price of its branded product. So where have those plans been for the decade it's been selling the product?

Advertisement
X

Subscribe and SAVE 50%

View our best offer
Subscribe to Print